ATE329926T1 - Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten - Google Patents

Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten

Info

Publication number
ATE329926T1
ATE329926T1 AT97942549T AT97942549T ATE329926T1 AT E329926 T1 ATE329926 T1 AT E329926T1 AT 97942549 T AT97942549 T AT 97942549T AT 97942549 T AT97942549 T AT 97942549T AT E329926 T1 ATE329926 T1 AT E329926T1
Authority
AT
Austria
Prior art keywords
fragments
plasminogen
provides
methods
plasminogen activator
Prior art date
Application number
AT97942549T
Other languages
German (de)
English (en)
Inventor
Gerald Soff
Stephen T Gately
Przemyslaw Twardowski
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE329926T1 publication Critical patent/ATE329926T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97942549T 1996-09-17 1997-09-17 Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten ATE329926T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/710,305 US5801012A (en) 1996-09-17 1996-09-17 Methods and compositions for generating angiostatin

Publications (1)

Publication Number Publication Date
ATE329926T1 true ATE329926T1 (de) 2006-07-15

Family

ID=24853480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97942549T ATE329926T1 (de) 1996-09-17 1997-09-17 Verfahren und zusammensetzungen für die behandlung von neoplastichen krankheiten

Country Status (9)

Country Link
US (2) US5801012A (enExample)
EP (2) EP0964869B1 (enExample)
JP (1) JP4160121B2 (enExample)
AT (1) ATE329926T1 (enExample)
AU (1) AU4422797A (enExample)
CA (1) CA2265550A1 (enExample)
DE (1) DE69736129T2 (enExample)
ES (1) ES2267151T3 (enExample)
WO (1) WO1998015574A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US7297331B2 (en) * 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
CA2295925A1 (en) * 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
JP2002531385A (ja) * 1998-11-25 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー アンジオスタチンおよびプラスミノゲンのクリングル５領域を含む組成物およびその使用方法
EP1214346A1 (en) 1999-09-15 2002-06-19 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
WO2001058921A2 (en) * 2000-02-08 2001-08-16 Northwestern University Methods and compositions for generating angiostatin
CA2421251A1 (en) 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US7420036B2 (en) 2000-11-28 2008-09-02 Waisman David M Anti-angiogenic polypeptides
ITMI20011995A1 (it) * 2001-09-26 2003-03-26 Ist Naz Ricerca Sul Cancro Sostanze ad attivita' antinfiammatoria
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
WO2004054517A2 (en) * 2002-12-13 2004-07-01 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
US7141035B2 (en) * 2003-03-28 2006-11-28 Sherwood Services Ag Catheter with occlusion resistant tip
US7090654B2 (en) * 2003-03-28 2006-08-15 Sherwood Services Ag Catheter with occlusion resistant tip
US7776005B2 (en) * 2003-03-28 2010-08-17 Covidien Ag Triple lumen catheter with occlusion resistant tip
CN1889929B (zh) * 2003-11-14 2013-04-10 阿尔萨公司 药物递送媒介物中的赋形剂
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US9913962B2 (en) 2004-11-04 2018-03-13 Covidien Ag Catheter insertion apparatus
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2009100617A1 (zh) * 2008-02-04 2009-08-20 Shanghai First People's Hospital 抑制血管新生的多肽及其应用
WO2010151573A1 (en) 2009-06-26 2010-12-29 Tyco Healthcare Group Lp Catheterization system
CA2715857A1 (en) 2009-09-30 2011-03-30 Tyco Healthcare Group Lp Medical catheter having a design providing low recirculation and reversibility
US9072867B2 (en) 2011-09-30 2015-07-07 Covidien Lp Catheter with external flow channel
US8747343B2 (en) 2011-09-30 2014-06-10 Covidien Lp Hemodialysis catheter with improved side opening design
US9216163B2 (en) 2013-05-20 2015-12-22 Kyorin Pharmaceutical Co., Ltd. Method of inhibiting angiogenesis
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2431342C3 (de) * 1973-07-27 1978-10-26 Behringwerke Ag, 3550 Marburg Verfahren zur Messung des Plasminogengehaltes durch Bestimmung der Bildung von Fibrin in einer Probe
US4968494A (en) * 1987-03-27 1990-11-06 Merck & Co., Inc. Methods and compositions for thrombolytic therapy
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
DE68927904T2 (de) 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
ATE368051T1 (de) 1995-04-26 2007-08-15 Childrens Medical Center Angiostatinfragmente und verfahren für deren verwendung
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
WO1996041194A1 (en) 1995-06-07 1996-12-19 The Children's Medical Center Corporation Diagnosis, prognosis and monitoring of angiogenesis dependent diseases
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
CN1554444A (zh) 1995-12-13 2004-12-15 ��ͯҽѧ���Ĺ�˾ 内皮细胞增殖抑制剂及其应用方法
BR9708911A (pt) 1996-05-03 1999-08-03 Abbott Lab Composto fragmento de peptídeo processo par tratar uma doença em um paciente em necessidade de terapia antioangiogênese composição polinucleotídeo único ou de duplo-filamento isolado vetor e processo para produzir um fragmento de peptídeo de kringle 5 ou proteína de fusão de kringle 5 solúvel
CA2295925A1 (en) 1997-06-26 1999-01-07 Karolinska Innovations Ab Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo

Also Published As

Publication number Publication date
WO1998015574A1 (en) 1998-04-16
EP1705184A1 (en) 2006-09-27
ES2267151T3 (es) 2007-03-01
JP4160121B2 (ja) 2008-10-01
US5801012A (en) 1998-09-01
CA2265550A1 (en) 1998-04-16
AU4422797A (en) 1998-05-05
EP0964869B1 (en) 2006-06-14
DE69736129D1 (de) 2006-07-27
EP0964869A1 (en) 1999-12-22
US6576609B1 (en) 2003-06-10
EP0964869A4 (en) 2003-06-04
JP2001502534A (ja) 2001-02-27
DE69736129T2 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
DE69736129D1 (de) Verfahren und Zusammensetzungen für die Behandlung von neoplastichen Krankheiten
ATE459369T1 (de) Verfahren zur behandlung von entzündungen
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
ATE198712T1 (de) Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
DK0662827T4 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
NO995044L (no) Osteoprotegerinbindende proteiner og reseptorer
DE69921102D1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
PT87138A (pt) Process for the preparation of adn recombinant molecules codin g polypeptide adn segments and of antibody compositions relate d with human tissue factor
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
DK384084D0 (da) Vaeksthormonfrigoerende peptider samt fremgangsmaade til behandling af attedyr hermed
DK0953576T3 (da) Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
ATE377026T1 (de) Behandlung von fettleibigkeit
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ES2113878T3 (es) Proteina c hibrida.
Camacho et al. Limited proteolysis of tumor cells increases their plasmin-binding ability
ATE292471T1 (de) Peptide des tsp-i-rezeptors cd36 zur behandlung von krankheiten welche durch eine fehlregulation von tgf-beta1 verursacht werden
JPS5738716A (en) Incised wound treating composition
DE3883315D1 (de) Neue fibrinolytische enzyme.
DE3751218D1 (de) Verfahren und therapeutische Zubereitungen für die Behandlung von Gerinnungsstörungen.
PT639225E (pt) Polipeptidos e peptidos novos acidos nucleicos que codificam para aqueles e sua utilizacao na area da terapia tumoral inflamacao ou imunologia
WO2001058921A3 (en) Methods and compositions for generating angiostatin
KR900702017A (ko) 혼성 단백질(bybrid proteins)
ATE260340T1 (de) Molekulare klonierung und charakterisierung von molekülen, welche verwandt sind mit relaxin und liganden der insulinfamilie
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0964869

Country of ref document: EP

REN Ceased due to non-payment of the annual fee